Before the era of molecular targeting drugs, cytokine therapy with interferon (IFN) or interleukin-2 (IL-2) was widely used, and partial response (PR) and complete response (CR) were achieved in 15.9% and 1.8%, respectively, of patients with advanced RCC treated with IFN (1). The gene discussed is IFNA1; the disease is renal cell carcinoma.